fbpx

Healthcare

Should I Stop Vaping?

Over the past few weeks we’ve seen a surge of headlines that say vaping may be more harmful than we might have initially thought. Seven deaths have been linked to the use of e-cigarettes. In response, some states have banned vaping products. However, naysayers — including experts — argue that a knee-jerk reaction by health agencies is premature, overlooks the harm reduction that vaping achieves, and could cause a potential public health disaster

If smoking is the de facto predecessor of vaping, then e-cigarettes should be examined within the context of nicotine delivery systems as a whole. Smoking is the leading cause of preventable death in the United States. Should the risk associated with vaping be a deterrent when the alternative is smoking cigarettes?

Some in the recovery community say that it shouldn’t. Many former cigarette smokers have replaced their “analog” smokes with e-cigarettes, using vaping as a means of harm reduction that swaps out cancer-causing tobacco with a safer means of nicotine delivery. Recovery purists and some clinicians, however, argue that smokers are trading one addiction for another and express concerns that, lower risk or not, most vapers are still ingesting large amounts of highly addictive nicotine. They also point to this recent rash of deaths as evidence against vaping.

Before we address the question of harm reduction, though, do the alarming headlines have any merit in science? And given that e-cigarettes have been around for 15 years, why are we only seeing deaths now?

RECENT MEDIA COVERAGE OF VAPING

The American Medical Association (AMA) recently labeled vaping “an urgent public health epidemic,” and physicians have urged the Food and Drug Administration (FDA) to act. The AMA claims that research has shown that the use of e-cigarettes and vaping products is unsafe and causes addiction, however the statement does not provide the supporting research. The AMA also says they “applaud steps to remove flavored e-cigarette products from the market.”

The Centers for Disease Control and Prevention (CDC) issued a statement that together with the FDA, local health departments, and other clinical and public health partners, they are investigating a multi-state outbreak of lung disease associated with e-cigarette products. The FDA echoed the CDC’s concern, calling the outbreak “a frightening public health phenomenon.”

Dr. Dana Meaney-Delman, who is leading the CDC’s investigation, said in a statement, “The recent rise of acute lung illnesses linked to vaping has deepened concerns about the safety of the devices.” 

But why now? People have been vaping for over a decade. The CDC’s Meaney-Delman says, “We’re all wondering if this is new or just newly recognized.”

Here’s what we know: As of this writing (9/21/19), the CDC states that 530 cases of lung illness have been reported from 38 states, and seven deaths have been attributed to vaping. Most affected patients also reported a history of using vaping products that contain THC. 

The CDC does not yet know the specific causes of these illnesses: “The investigation has not identified any specific e-cigarette or vaping products (devices, liquids, refill pods, and/or cartridges) or substance that is linked to all cases.” Regardless, for those who are concerned with these issues, the CDC recommends refraining from using all vaping or e-cigarette products until they know more.

Elsewhere on the website, the CDC still states that e-cigarettes have the potential to benefit adult smokers as a substitute for regular cigarettes.

E-CIGARETTE BANS GOING INTO EFFECT

Because of the media coverage and caution by public health agencies, we are seeing increasing action across the US: New York’s former mayor, Michael R. Bloomberg, has committed $160 million to ban flavored e-cigarettes, Governor Gretchen Whitmer issued an executive order to ban the sale of flavored vaping products in Michigan, San Francisco has banned the sale of e-cigarettes, and President Donald Trump says the FDA will ban flavored e-cigarettes. 

Is this a knee-jerk reaction? It seems that some of the pressure is a result of parents and politicians who are concerned that flavored vaping products are responsible for the surge in teen use. That’s understandable, given the potential for nicotine to harm the developing brain. According to the CDC, one in five high schoolers and one in 20 middle schoolers vape.

For adults, however, there appears to be conflicting statements by researchers, doctors, and health officials. 

In a September 2019 article, Dr. Robert Shmerling at Harvard echoed the CDC’s bottom line: Experts are unsure if vaping is causing these lung problems, and lung disease has not been linked to a specific brand or flavor of e-cigarette. A more likely culprit, they claim, is a chemical contaminant within the inhaled vapors that is causing an allergic reaction or immune system response. 

This belief is supported by a study that came out last year linking the chemical flavors within e-cigarettes to an adverse effect. Dr. Sven-Eric Jordt, PhD, one of the authors of the study, recently told The Guardian that “the liquids vaporised by e-cigarettes are chemically unstable and form new chemicals that irritate the airways and may have other toxic effects.” These new chemicals are not disclosed by the manufacturers to users. 

Dr. Michael Siegel, a professor at Boston University, claims that health officials and physicians are not telling the full story: In every case in which a specific e-liquid has been identified, that e-liquid has been found to contain THC — a fact corroborated by the CDC. He states that the e-liquids in some of these cases were oil-based and typically purchased off the street; therefore, their ingredients are not strictly regulated. It is these oil-based THC liquids that are known to cause acute respiratory illness. 

Similarly, the Washington Post reported that the FDA investigation found the same vitamin E-derived oil in cannabis products that were used by those found to be suffering vaping-related illnesses throughout the country. 

CDC’S GUIDELINES: UNNECESSARILY BROAD

While Siegel acknowledges we aren’t in a position to draw conclusions about THC oils or to say that street products are definitely to blame, he believes the CDC’s recommendations are unnecessarily broad and consequently harmful, since people who vape may think it’s safer to go back to smoking cigarettes. 

“I cannot overemphasize how insane this policy is,” he says. “From a public health perspective, it makes absolutely no sense to ban these fake cigarettes but to allow the real ones to remain on the shelves.”

Instead, Siegel suggests, the CDC could offer more specific and useful guidance to the public, specifically: Do not vape THC oils (including butane hash oil), do not use any oil-based vaping e-liquid product, and refrain from buying products off the street or using any e-liquid that doesn’t disclose its ingredients. To reduce risk, people should “stick to products being sold at retail stores, especially closed cartridges where there is no risk of contamination or the presence of unknown drugs.”

Switching from smoking tobacco to e-cigarettes is a proven harm reduction strategy supported by health officials and used by individuals in recovery. 

Lara Frazier, a person in long-term recovery, explained, “I am in abstinence-based recovery and quit smoking cigarettes over four years ago, thanks to e-cigarettes.” Regarding the recent deaths associated with vaping, she says: “There is mass hysteria about vaping, with people not being properly educated on what is actually occurring.”

Frazier is concerned about the consequences of recent official warnings: “Nicotine addiction is like any addiction, and banning flavors will likely not result in less nicotine being smoked. This could cause more harm because the teenagers will have to find black-market cartridges, make their own juice, and/or switch to smoking cigarettes.”

She continues, “I think it’s ridiculous that they are going to ban all flavored juices that aren’t tobacco-based on five (now seven) deaths and illness without properly looking at the data or researching the cause of the illness.”

VAPING AS HARM REDUCTION

There is world-wide support and evidence for vaping as harm reduction. A study conducted by the New England Journal of Medicine found that vaping was nearly twice as effective as conventional nicotine replacement products for smoking cessation.

In the UK, Public Health England also supports vaping as a harm reduction strategy. Even in light of the recent concerns, their position has stayed the same: “Our advice on e-cigarettes remains unchanged — vaping isn’t completely risk-free but is far less harmful than smoking tobacco. There is no situation where it would be better for your health to continue smoking rather than switching completely to vaping,” they said.

Yaël Ossowski, deputy director of the Consumer Choice Center, urged President Trump to consider the facts before reacting hastily and pushing for a ban, arguing that vaping is a less harmful alternative for consuming nicotine. Ossowski cites a 2016 report by the UK’s Royal College of Physicians, which reviewed the science, public policy, regulation, and ethics surrounding vaping and concluded that e-cigarettes should be promoted widely as a substitute for smoking. The report also sought to clear up misinformation about vaping and long-term harm, stating that while there is a possibility of harm from e-cigarettes, it is unlikely to exceed five percent of that associated with tobacco products. 

SMOKING CIGARETTES IS STILL THE LEADING CAUSE OF PREVENTABLE DEATH

According to the Centers for Disease Control and Prevention, more than 16 million Americans are living with a disease caused by smoking. We have abundant evidence that smoking leads to disease and disability, harming nearly every organ in the body. It causes cancer, heart disease, stroke, lung diseases, diabetes, and chronic obstructive pulmonary disease. It also increases the risk for tuberculosis, eye diseases, and autoimmune conditions. 

Worldwide, the use of tobacco products is responsible for more than seven million deaths each year. In the U.S., 480,000 people die every year from smoking, and 41,000 people die as a result of secondhand smoke. Economically, smoking has a huge impact on the United States: it costs $170 billion a year in direct medical care, and $156 million in lost productivity. 

Smoking remains the leading cause of preventable death. 

At this point, the evidence supports vaping as an effective means of harm reduction, thus outweighing the limited risks. Further, public health officials have yet to complete their investigations into these risks so they can conclusively identify the cause of the deaths attributed to vaping. It seems foolish to enforce blanket bans on e-cigarettes, as that may cause further harm by pushing people toward buying black-market vaping products or resuming smoking cigarettes.

Read more here

What happened to the right to choose your healthcare?

From atop the lecterns at the Democratic presidential debates and the White House, a common trope is dismantling and rejiggering how healthcare is delivered in America.

For the left, the emphasis is on expanding who can access government-backed health insurance programs while cutting off the role of the private sector. On the right, President Trump is looking to import drugs and pharmaceutical price controls from abroad.

Missing in both of these visions is the essential component that governs every other sector of the economy: the freedom to choose.

Much like housing, transportation, and education, it’s clear that the entire healthcare sector needs disruption.

We need out-of-the-box thinking, innovation, and on-demand delivery that will bring costs down for ordinary people. It’s this formula that has empowered millions to rise out of poverty, make a decent living for their families, and expand consumer choice to makes their lives better.

But both the Democrats and Trump are leading Americans astray on what really matters when it comes to healthcare.

Sens. Bernie Sanders, Elizabeth Warren, Cory Booker, and Kamala Harris have serious proposals to totally ban the private healthcare market in favor of a “Medicare For All” system. That means every American would be thrown into the government insurance program reserved for our seniors.

All administration, billing, reimbursement claims, and hospital contracts for over 350 million people would be handled by the federal government. For a country as unique, diverse, and large as the United States, this just couldn’t be carried out effectively. The CBO’s analysis of a single-payer system admits that new taxes and an entirely new administrative bureaucracy would take years to implement.

Such plans would make it illegal for Americans to choose the type of healthcare coverage that fit them best, depriving them of fundamental choices.

This makes two grandiose and flawed assumptions. One, that a top-down government reorganization of insurance and health services would be the best method to deliver healthcare, and two, that the individual consumer cannot be trusted to make decisions about their care. That is wrong.

People choose different healthcare plans depending on their employment situation, their age, or their lifestyle.

Many younger working people, such as myself, don’t have comprehensive insurance because it doesn’t make economic sense. We’d rather pay out of pocket for small expenses and use high-deductible disaster insurance when necessary. The young and healthy tend to shy away from the large insurance plans for these very reasons.

For the 8.8 percent of Americans without health insurance, would they benefit from a mass reorganization of the system that would offer the care reserved for our seniors if the cost comes in the form of higher taxes and less consumer choice?

The same applies to Trump’s well-intended but flawed plans on importing drugs from single-payer systems around the world.

The reason pharmaceutical drugs are more expensive has more to do with subsidies than cost. Most drugs are born from innovative American firms but are subsidized greatly or negotiated for lower rates by governments who import them. Firms can afford this because it’s offset by American prices, meaning the rest of the world is freeriding on American innovation and intellectual property.

They achieve this by reducing access and choice. It’s no secret that the lion’s share of pharmaceutical drugs are available in the U.S. while they’re unavailable in the countries that refuse to pay for them. So yes, the prices of drugs may be cheaper in Canada or Norway, but the supply and choices are lacking. Do we want fewer choices of drugs for lower costs or more choices and prices at market rate?

What matters most when it comes to our personal health is the freedom to choose. Whether that it’s our doctor, insurance program, or drugs we buy, Americans want to be able to pick what works best from them. Grandiose plans that seek to completely reorganize how many taxes we pay and how we receive care would severely restrict that.

That may be a well-intended path, but one that millions of Americans are right to reject.  

Yaël Ossowski is deputy director of the Consumer Choice Center

Published in the Chicago Tribune: https://www.chicagotribune.com/lifestyles/health/sns-tns-bc-healthcare2-commentary-20190815-story.html

Published in Globe Gazette: https://globegazette.com/opinion/columnists/commentary-what-happened-to-the-right-to-choose-your-health/article_b941a988-7864-51e5-98e2-5e987626ce16.html?utm_source=dlvr.it&utm_medium=twitter

Published in Duluth News Tribune: https://www.duluthnewstribune.com/opinion/columns/4636779-National-View-Column-Americans-deserve-the-right-to-choose-their-health-care

Liberals want to build their campaign around pharmacare, but ignore where drugs would end up

Fred Roeder is a health economist and the managing director of the Consumer Choice Center. David Clement is the North American-affairs manager for the Consumer Choice Center.

Internal documents from within the Liberal Party recently showed that Ontario Liberal MPs want 2019’s election campaign to be built on a national pharmacare plan.

Specifically, the proposed plan would seek to centralize and consolidate the 46 drug-procurement programs that exist in Canada. The goal would be to give Canada as a whole more bargaining power in the drug-procurement process, which would potentially lower the prices Canadians pay for their medicine. Although pharmacare could lower drug prices in the short run, it could also run the risk of exacerbating Canada’s existing drug shortage, and significantly limit patient access in the long run.

If a national pharmacare plan were to work, as advertised, it would help Canadian patients by lowering the price they pay for medicine. Unfortunately, the Liberals are largely ignoring the issue of where much of these low-priced drugs would end up, which is the United States. It is one thing to lower drug prices for Canadians, but that benefit isn’t realized if Canadian patients never actually have access to those cheaper drugs.

Pharmacare would be an attempt to further control the price of drugs. The problem is that Canada already has price-control mechanisms for prescription drugs at the federal and provincial level. Those price controls lead to much lower drug prices compared with the prices paid south of the border. That said, because Canadian drugs are cheaper than in the United States, several U.S. states have begun looking at importing pharmaceutical products from Canada in an attempt to undercut U.S. prices. For example, the Republican Governor of Florida has recently pushed for federal approval for drug importation from Canada, and U.S. President Donald Trump has already signalled his support of this measure.

And while importation from Canada to the United States could mean lower drug prices for patients in Florida, Canadian patients could suffer as a result of worsening access. U.S. Health Secretary Alex Azar has publicly stated that Canada doesn’t have the appropriate supply to meet patient demand, and that large pharmaceutical companies are unlikely to increase their supply for the Canadian market. Worsening drug shortages are the most likely outcome for Canadians if the federal government adds in more price controls while having large-scale drug exports to the United States. We know that this is the probable outcome because Canada already suffers from a lack of supply, and another measure to intervene on pricing will simply increase the incentive for American states to import from Canada.

Supply is one problem for Canadian patients, but it isn’t the only issue they face, and it isn’t the only issue that could get worse as a result of pharmacare. In addition to poor supply, Canada is significantly lagging in terms of access to potentially life-saving and innovative medicines. Countries such as Germany, Japan and the United States all introduce, and reimburse for, innovative drugs quicker than in Canada. Here, it takes more than 450 days for a new drug to be reimbursable, while that number is only 180 days in the United States. It can be expected that a pharmacare plan would make this innovation problem worse. It is unlikely that the manufacturers of these drugs will want to roll out innovative medicines in Canada, under various forms of price control, if those drugs can then be resold into other markets, undercutting prices abroad.

For cost, it is important to remember that Canadians have lower drug prices than Americans. At the same time, it is important to be aware that because of price controls, Canada is not a significant market for drug manufacturers, especially when compared with the United States, which accounts for more than 50 per cent of the industry’s global profits. If Canada goes too bullish against drug prices, while at the same time allowing American states to import prescription drugs from Canada, we might run the risk of drug companies leaving entirely, or massively delaying the introduction of new drugs in Canada.

Companies leaving the domestic market entirely might sound like a far-fetched concept, but it is something the Canadian marketplace has seen in other industries. Take Google and the recent issue of political advertising in Canada. Ottawa significantly changed its election advertising regulations, and rather than comply, Google decided that it would leave the political advertising market altogether. Thus, we have a large multinational entity cutting itself out of the political advertising market because conditions aren’t ideal, and because Canada’s market is minuscule in comparison to others.

Everyone wants more competitive and better pricing for patients. Unfortunately, the elephant in the room is where these price-controlled drugs end up, and how industry will respond. Our concern, as a consumer group, is that the pharmacare plan, without addressing export, could exacerbate the already serious issue of drug availability in Canada.

If a provider of vital pharmaceuticals were to pull out of the Canadian market as a result of price fixing and undercutting, it would be Canadian patients who pay the ultimate price. Drug access – especially to new innovative treatments – lags in Canada, and without the foresight to correct some of these blind spots, access could either get significantly worse, or be eliminated altogether under a national pharmacare plan. That scenario should concern all Canadians.

Read more here

Cuomo’s Out of Control Craving for an Opioid Slush Fund

Sometimes a bad idea is a bad idea, no matter how you package it. New York Governor Andrew Cuomo is trying again, after his $600 million opioid tax was slapped down in December by an Obama appointed federal judge. Proponents of the earlier tax scheme pointed to a key provision which forbade manufacturers from passing along […]

Dental therapists not free market solution to dental woes

When healthcare reform is invoked in politics, there’s one area left out too often: our teeth. According to the CDC, only 64 percent of adults had a dental appointment last year. In Broward County, 19 percent of adults didn’t see a dentist in 2017 because of cost. That’s appalling. And in more rural parts of the country, dentists are hard […]

Dental therapists are no free market solution to dental woes

The current state of dental care in Florida is a mess. Florida lawmakers are right to address it. However, the proposed solution of midlevel providers called dental therapists in SB 1498 misses the mark and is anything but a market solution. Dental therapists require less training and education than dentists and can perform a fraction of […]

A Patently Reasonable Approach to Addressing Pharmaceutical Prices

We seem to be at an impasse when it comes to getting the prices of prescription drugs under control for patients while at the same time fostering innovation. This need not be the case. The left and the right have their own ideological approaches, none of which will advance given current political reality. Progress will […]

Warum sollen Arme Zölle auf Medikamente zahlen?

Due to a lack of basic conditions and a lack of infrastructure, donated drugs and vaccines often do not even reach patients. # EB144 Zeitgleich zum Weltwirtschaftsforum trifft sich Ende Januar unweit von Davos in Genf der geschäftsführende Vorstand der Weltgesundheitsorganisation. Erschütternde Nachrichten über erneute Ebola-Fälle aus dem Kongo sollten vermuten lassen, dass es sich […]

Huge disparities in European breast cancer care shown by new index

With nearly 100,000 women lose their life to breast cancer every year in the European Union it is the most lethal cancer diagnosis for women in the EU. And while health systems of the 28 different Member States have made progresses in providing better care, chances of early diagnosis and state of the art treatment depends heavily […]

Both parties can work together to lower drug prices

Healthcare was a key issue for voters in the split-decision midterm elections. So are we in for more partisan divide and no progress? Not necessarily. We simply need to reframe the debate to find common ground. The Democrat-controlled House won’t consider Obamacare repeal, and the Republican Senate won’t consider Medicare for all. But there are […]

Scroll to top
en_USEN